10th INTEREST Workshop on HIV

第十届 INTEREST 艾滋病毒研讨会

基本信息

  • 批准号:
    9141914
  • 负责人:
  • 金额:
    $ 7万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-03-01 至 2017-02-28
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant): The most recent UNAIDS estimates of the global burden of HIV are that 36.9 million people are currently living with HIV-1 infection and 25.8 million of them live in sub-Saharan Africa. Moreover, 70% of new infections annually are occurring in the same region of the world (UNAIDS. How AIDS Changed Everything; 2015). HIV incidence has been declining in many, but not all, African countries at a time that HIV prevalence continues to rise as more people access antiretroviral treatment. Although treatment is having important impact on slowing HIV transmission, alone it will not turn the epidemic on its head. HIV prevention remains critical to stem the tide of HIV. The UNAIDS 90-90-90 targets for 2020 aim for 90% of people living with HIV knowing their HIV status; 90% of people who know their HIV- positive status on antiretroviral treatment; and 90% of people on treatment with suppressed virus loads. The 2030 targets are 95-95-95 (UNAIDS. Fast-track: ending the AIDS epidemic by 2030; 2014). Current estimates for the African continent are that 29% of all those living with HIV have suppressed viral loads. Every step of the treatment cascade needs intensive investment: scaling up HIV testing access to diagnose those living with HIV, an immediate offer of antiretroviral treatment regardless of CD4 count, and retention in effective treatment to achieve viral suppression. Although there are many measures in place to tackle the HIV disease burden in Africa there remains much work to do in terms of training local physicians and scientists in regard to diagnosis, treatment, and management of individuals with HIV-1 infection, as well as to evidence-informed public health responses and implementation science to determine the most cost-effective use of financial and human resources. The International Workshop on HIV Treatment, Pathogenesis and Prevention Research in Resource- Limited Settings (INTEREST) Workshop was an initiative of Professors Joep M.A. Lange † (Amsterdam Institute for Global Health and Development (AIGHD), Academic Medical Center, Department of Global Health, University of Amsterdam) and Charles A.B. Boucher (Erasmus Medical Center, Rotterdam, University of Rotterdam). Together with a prominent group of international experts in the field of HIV, a focused international scientific meeting in Africa was launched in 2007. Since then, 9 successful annual meetings have been convened in Uganda, Senegal (twice), Zambia (twice), Mozambique, Tanzania, Kenya, and Zimbabwe. Known as the "African CROI" the INTEREST Workshop brings together scientists involved in HIV treatment, pathogenesis, and prevention research in Africa to share pivotal findings, promote collaboration, and transfer experiences across several fields and many continents. The organizers of the 2016 INTEREST Workshop will pursue the following objectives: 1) To showcase cutting-edge knowledge in the fields of HIV diagnosis, treatment, and prevention of HIV-1 infection. 2) To continue to foster the building of a community of African physicians and scientists who will discuss implementing local solutions for the management of patients living with HIV-1 infection and for the prevention of HIV transmission.
 描述(由申请人提供):联合国艾滋病规划署对全球艾滋病毒负担的最新估计是,目前有 3690 万人感染 HIV-1,其中 2580 万人生活在撒哈拉以南非洲地区,此外,70% 的新感染者。每年都会在世界同一地区发生(联合国艾滋病规划署。艾滋病如何改变一切;2015 年),在艾滋病毒流行持续的同时,许多(但不是全部)非洲国家的艾滋病毒发病率一直在下降。随着越来越多的人接受抗逆转录病毒治疗,尽管治疗对减缓艾滋病毒传播具有重要影响,但艾滋病毒预防仍然是遏制艾滋病毒流行的关键。到 2020 年,目标是让 90% 的艾滋病毒感染者知道自己的艾滋病毒状况;90% 的人知道自己正在接受抗逆转录病毒治疗;90% 的人接受病毒载量抑制治疗。 2030 年的目标是 95-95-95(联合国艾滋病规划署。快速通道:到 2030 年结束艾滋病流行;2014 年)。目前对非洲大陆的估计是,29% 的艾滋病毒感染者已经抑制了病毒载量。治疗级联需要大量投资:扩大艾滋病毒检测范围以诊断艾滋病毒感染者,无论 CD4 计数如何立即提供抗逆转录病毒治疗,并保留有效治疗以实现病毒抑制。尽管已采取许多措施来解决非洲的艾滋病毒疾病负担,但在对当地医生和科学家进行有关 HIV-1 感染者的诊断、治疗和管理以及以证据为基础的公共卫生应对措施和实施科学,以确定资源有限环境下艾滋病毒治疗、发病机制和预防研究国际研讨会(INTEREST)是教授们的一项倡议。乔普·M·A·兰格 † (阿姆斯特丹全球健康与发展研究所 (AIGHD)、学术医学中心、阿姆斯特丹大学全球健康系)和 Charles A.B. Boucher(鹿特丹大学伊拉斯姆斯医学中心)以及一群著名的国际专家。在艾滋病毒领域,2007年在非洲发起了一次重点关注的国际科学会议。此后,已在乌干达、塞内加尔(两次)、赞比亚(两次)、莫桑比克、坦桑尼亚、肯尼亚和津巴布韦被称为“非洲 CROI”,INTEREST 研讨会汇集了非洲从事艾滋病毒治疗、发病机制和预防研究的科学家,分享关键发现、促进合作并在多个领域和许多领域交流经验。 2016 年 INTEREST 研讨会的组织者将追求以下目标: 1) 展示 HIV 诊断、治疗和预防 HIV-1 感染领域的前沿知识。这是一个由非洲医生和科学家组成的社区,他们将讨论实施本地解决方案来管理 HIV-1 感染患者和预防 HIV 传播。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Ending AIDS as a public health threat by 2030: Scientific Developments from the 2016 INTEREST Conference in Yaoundé, Cameroon.
到 2030 年消除艾滋病这一公共卫生威胁:2016 年喀麦隆雅温得 INTEREST 会议的科学进展。
  • DOI:
  • 发表时间:
    2017
  • 期刊:
  • 影响因子:
    1.2
  • 作者:
    Hankins, Catherine A;Koulla;Kilmarx, Peter;Ferrari, Guido;Schechter, Mauro;Kane, Coumba Touré;Venter, François;Boucher, Charles Ab;Ross, Anna;Zewdie, Debrework;Eholié, Serge Paul;Katabira, Elly
  • 通讯作者:
    Katabira, Elly
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Guido Ferrari其他文献

Guido Ferrari的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Guido Ferrari', 18)}}的其他基金

SOSIP-NP/mRNA combination for novel preventive and therapeutic HIV-1 vaccine regimens
用于新型预防性和治疗性 HIV-1 疫苗方案的 SOSIP-NP/mRNA 组合
  • 批准号:
    10696131
  • 财政年份:
    2022
  • 资助金额:
    $ 7万
  • 项目类别:
SOSIP-NP/mRNA combination for novel preventive and therapeutic HIV-1 vaccine regimens
用于新型预防性和治疗性 HIV-1 疫苗方案的 SOSIP-NP/mRNA 组合
  • 批准号:
    10461584
  • 财政年份:
    2022
  • 资助金额:
    $ 7万
  • 项目类别:
SOSIP-NP/mRNA combination for novel preventive and therapeutic HIV-1 vaccine regimens
用于新型预防性和治疗性 HIV-1 疫苗方案的 SOSIP-NP/mRNA 组合
  • 批准号:
    10696131
  • 财政年份:
    2022
  • 资助金额:
    $ 7万
  • 项目类别:
Linking Antibody Cooperativity and Effector Cell Engagement
将抗体协同性和效应细胞参与联系起来
  • 批准号:
    10475288
  • 财政年份:
    2021
  • 资助金额:
    $ 7万
  • 项目类别:
Linking Antibody Cooperativity and Effector Cell Engagement
将抗体协同性和效应细胞参与联系起来
  • 批准号:
    10670258
  • 财政年份:
    2021
  • 资助金额:
    $ 7万
  • 项目类别:
Linking Antibody Cooperativity and Effector Cell Engagement
将抗体协同性和效应细胞参与联系起来
  • 批准号:
    10258151
  • 财政年份:
    2021
  • 资助金额:
    $ 7万
  • 项目类别:
Infectious Diseases in Africa: Correlates of Protection, Lessons from Vaccines and Natural Infection Studies
非洲传染病:保护的相关性、疫苗的经验教训和自然感染研究
  • 批准号:
    10361465
  • 财政年份:
    2020
  • 资助金额:
    $ 7万
  • 项目类别:
Infectious Diseases in Africa: Correlates of Protection, Lessons from Vaccines and Natural Infection Studies
非洲传染病:保护的相关性、疫苗的经验教训和自然感染研究
  • 批准号:
    10012379
  • 财政年份:
    2020
  • 资助金额:
    $ 7万
  • 项目类别:
14th International Conference on HIV Treatment, Pathogenesis, and Prevention Research (INTEREST)
第14届国际艾滋病毒治疗、发病机制和预防研究会议(INTEREST)
  • 批准号:
    10012378
  • 财政年份:
    2020
  • 资助金额:
    $ 7万
  • 项目类别:
2017 INTEREST Conference
2017年兴趣大会
  • 批准号:
    9349001
  • 财政年份:
    2017
  • 资助金额:
    $ 7万
  • 项目类别:

相似海外基金

The Hektoen Institute of Medical Research Site Consortium - Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) Operations and Collaborations Center (UM2 Clinical Trial Optional)
Hektoen 医学研究所站点联盟 - HIV/艾滋病干预青少年医学试验网络 (ATN) 运营和合作中心(UM2 临床试验可选)
  • 批准号:
    10709606
  • 财政年份:
    2022
  • 资助金额:
    $ 7万
  • 项目类别:
The Hektoen Institute of Medical Research Site Consortium - Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) Operations and Collaborations Center (UM2 Clinical Trial Optional)
Hektoen 医学研究所站点联盟 - HIV/艾滋病干预青少年医学试验网络 (ATN) 运营和合作中心(UM2 临床试验可选)
  • 批准号:
    10599560
  • 财政年份:
    2022
  • 资助金额:
    $ 7万
  • 项目类别:
Expansion of the efficacy trial of Tele-Harm Reduction into a federally qualified health center operated syringe services program.
将减少远程伤害的功效试验扩展到联邦合格的健康中心运营的注射器服务计划。
  • 批准号:
    10656900
  • 财政年份:
    2021
  • 资助金额:
    $ 7万
  • 项目类别:
Clinical Sciences Core (Core C)
临床科学核心(核心 C)
  • 批准号:
    10153672
  • 财政年份:
    2015
  • 资助金额:
    $ 7万
  • 项目类别:
Clinical Sciences Core (Core C)
临床科学核心(核心 C)
  • 批准号:
    10404935
  • 财政年份:
    2015
  • 资助金额:
    $ 7万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了